Positive Media Coverage Somewhat Unlikely to Impact Sierra Oncology (NASDAQ:DNAI) Share Price

Headlines about Sierra Oncology (NASDAQ:DNAI) have trended positive this week, according to Accern. The research firm ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Sierra Oncology earned a media sentiment score of 0.26 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.7911213076625 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

COPYRIGHT VIOLATION NOTICE: This report was first reported by Zolmax and is the property of of Zolmax. If you are accessing this report on another publication, it was illegally stolen and republished in violation of US & international copyright and trademark legislation. The original version of this report can be accessed at https://zolmax.com/investing/positive-media-coverage-somewhat-unlikely-to-impact-sierra-oncology-nasdaqdnai-share-price/1560323.html.

About Sierra Oncology

Sierra Oncology, Inc, formerly ProNAi Therapeutics, Inc, is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network.

Insider Buying and Selling by Quarter for Sierra Oncology (NASDAQ:DNAI)

Receive News & Ratings for Sierra Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Positive Media Coverage Somewhat Unlikely to Impact Sierra Oncology  Share Price
Positive Media Coverage Somewhat Unlikely to Impact Sierra Oncology Share Price
SCYNEXIS, Inc.  Receives Average Recommendation of “Buy” from Analysts
SCYNEXIS, Inc. Receives Average Recommendation of “Buy” from Analysts
EQT Midstream Partners, LP  Receives Average Rating of “Hold” from Analysts
EQT Midstream Partners, LP Receives Average Rating of “Hold” from Analysts
Tutor Perini Corporation  Given Consensus Rating of “Buy” by Brokerages
Tutor Perini Corporation Given Consensus Rating of “Buy” by Brokerages
Workday, Inc.  Receives Average Rating of “Hold” from Brokerages
Workday, Inc. Receives Average Rating of “Hold” from Brokerages
Alio Gold Inc  Receives Consensus Rating of “Buy” from Analysts
Alio Gold Inc Receives Consensus Rating of “Buy” from Analysts


Leave a Reply

 
© 2006-2017 Zolmax.